Workflow
睿智医药(300149) - 2024 Q4 - 年度业绩预告
300149ChemPartner(300149)2025-01-24 07:52

Financial Projections - The estimated net profit for 2024 is projected to be a loss between RMB 193 million and RMB 250 million, compared to a loss of RMB 916.75 million in the same period last year[3]. - The estimated loss excluding non-recurring items is projected to be between RMB 200 million and RMB 260 million, compared to a loss of RMB 919.32 million in the same period last year[3]. - The company expects to recognize an impairment loss on goodwill and long-term assets related to the acquisition of its subsidiary Shanghai Ruizhi, estimated between RMB 120 million and RMB 139.26 million[5]. - The impact of non-recurring gains and losses on the company's net profit is estimated to be between RMB 7 million and RMB 10 million, primarily from government subsidies and non-current asset disposal gains[6]. Audit and Reporting - The financial data presented is preliminary and has not yet been audited by the accounting firm, with final figures to be disclosed in the 2024 annual report[4]. Investor Guidance - The company emphasizes the need for investors to make cautious decisions and be aware of investment risks[7].